<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355888</url>
  </required_header>
  <id_info>
    <org_study_id>M05-10070</org_study_id>
    <nct_id>NCT00355888</nct_id>
  </id_info>
  <brief_title>Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I, Open Label Study of MBP-426 Given by Intravenous Infusion in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mebiopharm Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mebiopharm Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MBP-426 (liposomal oxaliplatin suspension
      for injection) is safe and effective in the treatment of advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase 1 Study Type (Interventional/Observational) Interventional Study Design Purpose:
      Treatment Allocation: Nonrandomized trial Masking: Open Control: Dose Comparison Assignment:
      Single Group Endpoint: Safety/Efficacy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity, determination of maximum tolerated dose (MTD), and recommended Phase 2 dose</measure>
    <time_frame>Within 21 days of treatment administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor shrinkage according to RECIST</measure>
    <time_frame>Measured every 6 weeks (i.e., every 2 cycles) while receiving study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limited exploratory assays</measure>
    <time_frame>Variable throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Open label study of MBP-426</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBP-426</intervention_name>
    <description>Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.</description>
    <arm_group_label>Open label study of MBP-426</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically-confirmed malignancy that is locally advanced or metastatic solid tumor
             and is refractory to standard therapy or for which conventional therapy is not
             reliably effective or no effective therapy is available

          -  18 years of age or older

          -  ECOG Performance Status of 0, 1, or 2

          -  Adequate clinical laboratory values:

               -  absolute neutrophil count greater than or equal to 1500 cells/microliter

               -  platelets greater than or equal to 100,000 cells/microliter

               -  serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) for the
                  institution

               -  creatinine clearance (calculated) &gt; 60 mL/min (using the Cockcroft-Gault
                  equation)

               -  bilirubin less than or equal to 1.5 x ULN

               -  alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to
                  2.5 x ULN (patients with known liver metastases may have up to 5 times ULN AST
                  and ALT levels).

          -  Ability to cooperate with treatment and follow-up schedules

          -  Negative pregnancy test and using at least one form of contraception as approved by
             the Investigator prior to study entry if a female patient of childbearing potential or
             a male patient with a female partner of childbearing potential

          -  Measurable disease as defined by RECIST criteria or non-measurable disease

          -  Patients with known brain metastases may be included as long as they have been
             clinically stable for one month or more, and are not receiving dexamethasone

          -  Ability to maintain a central intravenous access (e.g. PICC, Groshong, or Hickman
             line)

          -  Signed informed consent prior to the start of any study specific procedures

        Exclusion Criteria:

          -  Received previous anticancer chemotherapy, immunotherapy, radiotherapy or any other
             investigational therapy in the 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior
             to study entry

          -  Received extensive prior radiotherapy to more than 30% of bone marrow reserves, or
             prior bone marrow/stem cell transplantation

          -  Any concomitant condition that could compromise the objectives of this study and the
             patient's compliance

          -  Pregnant or lactating women

          -  Current malignancies of another type, with the exception of adequately treated in situ
             cervical cancer and basal cell skin cancer or have demonstrated no evidence of disease
             for 5 years or more

          -  Clinically evident HIV, HBV, or HCV infection

          -  Hematologic malignancy

          -  Documented or known bleeding disorder

          -  Requirements for therapeutic anticoagulation that increases INR or aPTT above the
             normal range (low dose deep vein thrombosis [DVT] or line prophylaxis is allowed)

          -  Congestive heart failure

          -  Greater than Grade 1 peripheral neuropathy according to the National Cancer
             Institute's Common Terminology Criteria for Adverse Events v3.0 (CTCAE version 3.0)

          -  History of allergic reactions to platinum-based or liposomal agents

          -  Creatinine clearance (calculated) less than or equal to 60 mL/min (using the
             Cockcroft-Gault equation)

          -  Receiving or initiating treatment with any other investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandria Phan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <last_update_submitted>November 27, 2014</last_update_submitted>
  <last_update_submitted_qc>November 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced or Metastatic Solid Tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

